Format

Send to

Choose Destination
Oncoimmunology. 2014 Jul 3;3(7):e941742. eCollection 2014.

Lenalidomide induces degradation of IKZF1 and IKZF3.

Author information

1
Brigham and Women's Hospital ; Boston, MA USA.

Abstract

Lenalidomide and its analogs, thalidomide and pomalidomide, specifically inhibit growth of mature B-cell lymphomas, including multiple myeloma, and induce interleukin-2 (IL-2) release from T cells. We recently found that this results from activation of the CRBN-CRL4 E3 ubiquitin ligase to degrade the lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos).

KEYWORDS:

lenalidomide; pomalidomide; thalidomide; ubiquitin

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center